Name | sphinx |
---|---|
Synonyms |
2-Furancarboxamide, 5-methyl-N-[2-(4-morpholinyl)-5-(trifluoromethyl)phenyl]-
MFCD07315693 5-Methyl-N-[2-(4-morpholinyl)-5-(trifluoromethyl)phenyl]-2-furamide |
Description | SPHINX is a selective SRPK1 inhibitor with an IC50 value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD[1]. |
---|---|
Related Catalog | |
Target |
IC50: 0.58 μM (SRPK1)[1] |
In Vitro | SPHINX (10 μM; 2 h) affects EGF-induced phosphorylation of SRSF1 and SRSF2[1]. SPHINX (5 μM; 24 h) reduces the expression of VEGF165 relative to GAPDH control either in primary RPE and ARPE-19 cell lines[1]. Western Blot Analysis[1] Cell Line: ARPE-19 cell line Concentration: 10 μM Incubation Time: 2 hours Result: Blocked EGF-induced phosphorylation of SRSF1 and SRSF2. |
In Vivo | SPHINX (10 ng; i.o. on laser photocoagulation day 0 and day 7) affects neovascular growth in vivo[1]. SPHINX (25 ng; i.o. on laser photocoagulation day 0 and day 7) affects the CNV area in CNV rats[1]. Animal Model: C57/B6 mice with laser-induced CNV[1] Dosage: 10 ng Administration: Intraocular injection; 10 ng on laser photocoagulation day 0 and day 7 Result: Significantly reduced neovascular growth compared with saline-injected controls. Animal Model: Norway Brown rats with laser-induced choroidal neovascularization[1] Dosage: 25 ng (10 ng/uL) Administration: Intraocular injection; 25 ng (10 ng/uL) on laser photocoagulation day 0 and day 7 Result: Significantly reduced the CNV area compared with saline injected controls. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 391.2±42.0 °C at 760 mmHg |
Molecular Formula | C17H17F3N2O3 |
Molecular Weight | 354.324 |
Flash Point | 190.4±27.9 °C |
Exact Mass | 354.119141 |
LogP | 4.01 |
Vapour Pressure | 0.0±0.9 mmHg at 25°C |
Index of Refraction | 1.555 |